New finding could lead to development of hundreds of new antibiotics

EU-funded scientists have discovered a new molecule in Streptomyces bacteria that could be exploited to make the bacteria produce hundreds of novel antibiotics. The work, which is published online by the Proceedings of the National Academy of Sciences (PNAS), was partly supported by the EU-funded ACTINOGEN (Integrating genomics-based applications to exploit actinomycetes as a resource for new antibiotics) project.

When colonies of bacteria such as Streptomyces are under stress and so more vulnerable to attack from other bacteria, a signal is sent out across the colony that stimulates the bacteria to make antibiotics as a defence mechanism.

Drug manufacturers have exploited this characteristic of the Streptomyces bacteria for some time, using certain strains to produce antibiotics on an industrial scale. In most of these cases, the compounds used to trigger the bacterial defence mechanism are relatively unstable.

In this latest piece of research, scientists from the University of Warwick and the John Innes Centre in the UK succeeded in identifying a much more stable group of compounds called 2-alkyl-4-hydroxymethylfuran-3-carboxylic acids (AHFCAs) that could have the potential to stimulate different pathways of antibiotic production in the bacteria. This could eventually lead to the development of many novel antibiotics.

Normally the amounts of these defence-mechanism-triggering compounds produced by the bacteria are too small for chemists to analyse easily. In this study, the scientists used the University of Warwick's 700 MHz NMR (Nuclear Magnetic Resonance) machine to identify the AHFCAs on the basis of just a few micrograms of material.

The chemists combined their newfound knowledge with information on the genetic sequences of some Streptomyces bacteria to show that the AHFCA group of compounds could potentially be used to stimulate the production of both known and new antibiotics. Their hypothesis was confirmed when they added the AHFCAs to colonies of the W81 strain of Streptomyces coelicolor; the bacteria produced methylenomycin antibiotics.

Although methylenomycins are a familiar type of antibiotic, the researchers believe that the AHFCAs could also control the production of novel types of antibiotic.

"Early results also suggest that this approach could switch on novel antibiotic production pathways in up to 50% of Streptomyces bacteria," said Dr Christophe Corre of the University of Warwick, the lead author of the paper. "With thousands of known members of the Streptomyces family that could mean that AHFCAs could unlock hundreds of new antibiotics to replenish our dwindling arsenal of effective antibiotic drugs."

The researchers are now on the lookout for funding to explore the properties of AHFCAs further.

The ACTINOGEN project received approximately EUR 9.4 million in EU funding through the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6).

For more information, please visit:

Proceedings of the National Academy of Sciences (PNAS), http://www.pnas.org

University of Warwick, http://www.warwick.ac.uk

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...